Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28090638 | 0.85 | ADORA2A (0.47) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL28568917 | 0.84 | LMNA (0.48) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL29516583 | 0.84 | LMNA (0.48) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL500715 | 0.80 | LMNA (0.56) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL28212978 | 0.78 | LMNA (0.54) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL22360955 | 0.78 | LMNA (0.54) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL26645766 | 0.77 | LMNA (0.49) | LMNAHTTADORA2AADORA1ALOX15 | |
| Water SCHEMBL28964119 | 0.76 | LMNA (0.52) | LMNAHTTADORA2AADORA1NPC1 | |
| Water SCHEMBL28150223 | 0.76 | LMNA (0.52) | LMNAHTTADORA2AADORA1NPC1 | |
| SCHEMBL65673 | 0.73 | KMT2A (0.59) | LMNAHTTADORA2AADORA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090429-A1 | ENGINEERED SPLIT LUCIFERASES | MONOD BIO, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260077068-A1 | ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-03-19 | — | — | US | claimed |
| US-20250075190-A1 | DE NOVO DESIGNED LUCIFERASE | UNIVERSITY OF WASHINGTON | 2025-03-06 | — | — | US | claimed |
| EP-4466280-A2 | DE NOVO DESIGNED LUCIFERASE | University of Washington (US) | 2024-11-27 | — | — | EP | claimed |
| US-20240016933-A1 | Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells | MASSACHUSETTS GEN HOSPITAL (US) | 2024-01-18 | — | — | US | claimed |
| US-20240002908-A1 | METHODS OF DETERMINING SURFACE GLYCAN DENSITY | MASSACHUSETTS GEN HOSPITAL (US) | 2024-01-04 | — | — | US | claimed |
| US-20230406839-A1 | Bifunctional Compounds And Methods Of Using The Same | THE GENERAL HOSPITAL CORPORATION | 2023-12-21 | — | — | US | claimed |
| EP-4240421-A1 | BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME | The General Hospital Corporation (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2023137417-A2 | DE NOVO DESIGNED LUCIFERASE | UNIVERSITY OF WASHINGTON (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2022099040-A1 | METHODS OF ANCHORING OR RECONSTITUTING ACTIVE MOLECULES ON METABOLICALLY LABELED CELLS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022099058-A1 | METHODS OF DETERMINING SURFACE GLYCAN DENSITY | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022099043-A1 | BIFUNCTIONAL COMPOUNDS AND METHODS OF USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-12 | — | — | WO | claimed |
| US-10202584-B2 | Red-shifted luciferase-luciferin pairs for enhanced bioluminescence | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-12 | — | — | US | claimed |
| US-20180057801-A1 | RED-SHIFTED LUCIFERASE-LUCIFERIN PAIRS FOR ENHANCED BIOLUMINESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-01 | — | — | US | claimed |
| WO-2026090429-A1 | ENGINEERED SPLIT LUCIFERASES | MONOD BIO, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12595504-B2 | Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2026-04-07 | — | — | US | disclosed |
| US-20260092308-A1 | ANALYTE DETECTION AND QUANTIFICATION | EARLY IS GOOD INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-6359091-B1 | AS DIELECTRICS IN SEMICONDUCTORS | THE DOW CHEMICAL COMPANY | 2002-03-19 | — | — | US | disclosed |
| WO-2001038417-A1 | POLYARYLENE COMPOSITIONS WITH ENHANCED MODULUS PROFILES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-3951941-A | POLYAZODYE | SAKAI CHEMICAL INDUSTRY COMPANY, LIMITED (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092308-A1 | ANALYTE DETECTION AND QUANTIFICATION | EPCAM, MUC1, KLK3 | LMNA 1245/4885HTT 3150/4885ADORA2A 652/4885 |
| US-20260077068-A1 | ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING | KCNN2, KCNN1, ATP1B2 | LMNA 2914/4885HTT 1720/4885ADORA2A 725/4885 |
| US-20240016933-A1 | Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells | CD4, CD14, CD69 | LMNA 3479/4885HTT 4481/4885ADORA2A 2378/4885 |
| US-12595504-B2 | Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples | MRPL21, PGLS, CLPP | LMNA 1978/4885HTT 3880/4885ADORA2A 3553/4885 |
| US-20180057801-A1 | RED-SHIFTED LUCIFERASE-LUCIFERIN PAIRS FOR ENHANCED BIOLUMINESCENCE | LUC7L2, SCLY, GLB1 | LMNA 1249/4885HTT 3573/4885ADORA2A 2930/4885 |
| US-10202584-B2 | Red-shifted luciferase-luciferin pairs for enhanced bioluminescence | LUC7L2, SCLY, GLB1 | LMNA 1249/4885HTT 3573/4885ADORA2A 2930/4885 |
| US-20230406839-A1 | Bifunctional Compounds And Methods Of Using The Same | PAICS, PAPSS1, GNE | LMNA 4029/4885HTT 3350/4885ADORA2A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.